Jon Najarian is also in the stock, looking for a $37 handle by Aug expiration. Options action both in the weeklies and out to Aug tell someone knows something we don't.
SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported that total revenues for the second quarter of 2014 are expected to be approximately $10.6 million. This exceeds guidance Ligand issued on May 7, 2014 for total revenues to be $9.0 million to $9.5 million. The incremental increase in revenue over previous guidance will result in additional earnings and cash-flow for the second quarter.
Separately, the Company’s Board of Directors has authorized a share repurchase program of up to $10 million over the next 12 months. With this authorization, the Company may repurchase common stock from time to time in open-market transactions.
“We are pleased with the financial performance of all aspects of our business and to be reporting second quarter revenues that are meaningfully above our previous guidance,” said Nishan de Silva, Chief Financial Officer of Ligand Pharmaceuticals, Inc. “Our diverse range of revenues is setting the foundation for continued growth in profits and cash flow from operations. We closed the second quarter with the highest cash balance we have had in more than two years while paying down debt during that period, and now will be debt free at the end of this month. We are pleased to be in a position to put some of our cash to work under this newly authorized share repurchase program.”
Stock may have gotten ahead of itself, but shorts and Yellen aren't helping. I would buy some put protection, just in case earnings disappoint. This may also be a hint that someone knows something we don't. I know this is a negative take on what is otherwise a very good company, but LGND was $66 just a few trading sessions ago.
KOG has too much debt to warrant a better offer. They tried to market themselves several yearsago but there were no takers. They do better under Whiting.
DDD could so be an acquirer. I agree with you Scott; big banks are going nowhere, retail is soft, and RE sucks. 3D and biotech are where it's at, but you've got to buy some put protection in this market, and find a good entry point while you're at it. I like DDD in the mid-$50's.
Mid $50's looks like a good entry point with no bad news. But DDD can still be volatile. Doesn't hurt to buy a put option just in case. But I agree with you - going higher. And if acquisition talk begins to surface, we could go a whole lot higher.
Don't rule out consolidation. HP is a bit late to the party. It would take them years to become a serious 3D player. A more likely scenario is an acquisition of DDD.
No one can predict when PCYC will return to $102. But I wouldn't be surprised to see it at $200 within a few months.
Too early to sell the news. POWR has a lot or recovery upside yet. Probably won't go back to $21 anytime soon, but much upside remains from here, though it won't be a straight line.
Dying company? Really? Where did you get your finance degree? Harvard Junior College in Waco TX?
Aware of Soros and VRX, bought in myself today. Just hope VRX and Ackerman can pull it off. Can't say they haven't sweetened the pot enough.
I tried to buy some Jan 16 in-the-money call options on GTLS today. Wwwwaaaayyyy too expensive. I challenge anyone who thinks this stock is going to go much lower to look at the call options. Somebody believes GTLS is going to recover, and recover quickly. So I bought the stock at $74.90 instead. Strong balance sheet, plenty of cash, looks to me as if their investing in plant and equipment to set up for the next step up in revenue. Stop loss at $67, but don't think it's going there, especially with the bond market not looking so hot.